ArticleBioorganic & medicinal chemistry letters2009
Identification of novel agonists of the integrin CD11b/CD18.
Article in Bioorganic & medicinal chemistry letters, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 21 citations in OpenAlex.
- Mechanosensitivity of macrophage polarization: comparing small molecule leukadherin-1 to substrate stiffness.Frontiers in immunology · 2025Article
- Conjecturing about Small-Molecule Agonists and Antagonists of α4β1 Integrin: From Mechanistic Insight to Potential Therapeutic Applications.Biomedicines · 2024Review
- Design and Pharmacological Characterization of αJournal of medicinal chemistry · 2023Article
- CD11b suppresses TLR activation of nonclassical monocytes to reduce primary graft dysfunction after lung transplantation.The Journal of clinical investigation · 2022Article
- CD11b-Based Pre-Targeted SPECT/CT Imaging Allows for the Detection of Inflammation in Aortic Aneurysm.Journal of inflammation research · 2022Article
- GB1275, a first-in-class CD11b modulator: rationale for immunotherapeutic combinations in solid tumors.Journal for immunotherapy of cancer · 2021Review
- The Promiscuous Profile of Complement Receptor 3 in Ligand Binding, Immune Modulation, and Pathophysiology.Frontiers in immunology · 2021Review
- Identification of Oleanolic Acid as Allosteric Agonist of Integrin αFrontiers in pharmacology · 2021Article
- Can Integrin Agonists Have Cards to Play against Cancer? A Literature Survey of Small Molecules Integrin Activators.Cancers · 2017Review
- CD11b activation suppresses TLR-dependent inflammation and autoimmunity in systemic lupus erythematosus.The Journal of clinical investigation · 2017Article
- The complement receptor 3 (CD11b/CD18) agonist Leukadherin-1 suppresses human innate inflammatory signalling.Clinical and experimental immunology · 2016Article
- 99mTc-labelled anti-CD11b SPECT/CT imaging allows detection of plaque destabilization tightly linked to inflammation.Scientific reports · 2016Article
- Efficacy of Leukadherin-1 in the Prevention of Hyperoxia-Induced Lung Injury in Neonatal Rats.American journal of respiratory cell and molecular biology · 2015Article
- Agonist leukadherin-1 increases CD11b/CD18-dependent adhesion via membrane tethers.Biophysical journal · 2013Article
- New therapeutic approaches for protecting hematopoietic stem cells in aplastic anemia.Immunologic research · 2013Review
- Adhesion maturation of neutrophils on nanoscopically presented platelet glycoprotein Ibα.ACS nano · 2013Article
- Small molecule agonists of integrin CD11b/CD18 do not induce global conformational changes and are significantly better than activating antibodies in reducing vascular injury.Biochimica et biophysica acta · 2013Article
- Complement receptor 3 influences toll-like receptor 7/8-dependent inflammation: implications for autoimmune diseases characterized by antibody reactivity to ribonucleoproteins.The Journal of biological chemistry · 2013Article
- Small molecule-mediated activation of the integrin CD11b/CD18 reduces inflammatory disease.Science signaling · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
Abstract
We report the identification of novel small molecule agonists of integrin CD11b/CD18, which increased, in a dose-dependent manner, the adhesion of the integrin CD11b/CD18 expressing cells to two physiologically relevant ligands: Fibrinogen and iC3b. Compound 6 showed an ex vivo EC(50) of 10.5 microM and in vitro selectivity for binding to the recombinant alphaA-domain of CD11b/CD18. In silico docking experiments suggest that the compounds recognized a hydrophobic cleft in the ligand-binding alphaA-domain, implying an allosteric mechanism of modulation of integrin affinity by this novel compound.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.